FDA provides new information on Essure device
Yesterday, on August 11, 2020, the FDA posted the first spreadsheet of adverse event reports.
The Food and Drug Administration (FDA) continues its post-market evaluations of Essure devices and aims to keep information as updated as possible. Yesterday, on August 11, 2020, the FDA posted the first spreadsheet of adverse event reports.
The information was obtained via social media sources and, as such, may reference information already reported to the FDA. The information in the spreadsheet may not represent new adverse events.
In this spreadsheet, the FDA reviewed reportable events, with the nature and severity of the reports consistent with Medical Device Reports (MDRs) received for Essure since 2017.
The reports mentioned above were received from Bayer, manufacturer and seller of Essure until 2018. From now until April 2021, Bayer will continue to provide spreadsheets of reports and provide analysis reports detailing the information.
View the 522 post-market surveillance studies here.
Recap on reproductive rights with David Hackney, MD, MS
December 20th 2022In this episode of Pap Talk, we spoke with David Hackney, MD, MS, maternal-fetal medicine physician at Case Western Reserve University and chair of ACOG's Ohio chapter for a full recap of where restrictions on reproductive rights have been and where they're going.
Listen
In this episode of Pap Talk, Gloria Bachmann, MD, MSc, breaks down what it means to be a health care provider for incarcerated individuals, and explores the specific challenges women and their providers face during and after incarceration. Joined by sexual health expert Michael Krychman, MD, Bachmann also discusses trauma-informed care and how providers can get informed.
Listen
Preference for alternative contraceptive sources reported by many patients
October 31st 2024With nearly half of short-acting contraceptive users preferring non-traditional sources such as telehealth and over-the-counter options, a recent study highlights evolving patient needs in contraceptive access.
Read More
